Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials
交叉验证研究：III类β-微管蛋白作为切除术后非小细胞肺癌辅助化疗获益预测标志物的价值：四项随机试验的分析
期刊:Annals of Oncology
影响因子:65.4
doi:10.1093/annonc/mdr033
Reiman, T; Lai, R; Veillard, A S; Paris, E; Soria, J C; Rosell, R; Taron, M; Graziano, S; Kratzke, R; Seymour, L; Shepherd, F A; Pignon, J P; Sève, P
